Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 249-253

  Beri, R ^a   Chunduri, S ^a   Sweiss, K ^a   Peace, D J ^a   MacTal Haaf, C ^a   Dobogai, L C ^a   Shord, S ^a   Quigley, J G ^a   Chen, Y H ^a   Mahmud, N ^a   Rondelli, D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

AUC; BU; Hematopoietic SCT; Pharmacokinetics; Test dose

Indexed keywords

BUSULFAN; FLUDARABINE; ITRACONAZOLE; LORAZEPAM; ONDANSETRON; PARACETAMOL;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; EPILEPTIC DISCHARGE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AREA UNDER CURVE; BUSULFAN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 76749147839     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.133     Document Type: Article

References (20)

1. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820-826.
2. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912-3918. (Pubitemid 37486970)
3. Anderson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6: 548-554.
4. Fernandez HF, Tran HT, Federico A, Lennon S, Caldera H, Goodman MS. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice daily or daily schedule to patients with advanced hematology malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 486-492.
5. Madden T, De Lima M, Thapar N, Nguyen J, Roberson S, Couriel D. Pharmacokinetics of once daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6 h dosing schedule. Biol Blood Marrow Transplant 2007; 13: 56-64.
6. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476.
7. De Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
8. Kangarloo S, Naveed F, Anderson B. Individualized once daily dosing of intravenous Busulfan: a pharmacokinetic study in patients undergoing conditioning for allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005; Tandem BMT meeting, Abstract no. 98.
9. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145-154.
10. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N et al. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 477-482.
11. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH et al. Fludarabine/I.V. BU conditioning regimen: myeloablative, reduced intensity or both? Bone Marrow Transplant 2008; 41: 935-940.
12. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
13. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of test dose of intravenous Busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous Busulfan in children undergoing a reduced intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 472-479.
14. Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H. Lorazepam for seizure prophylaxis during high-dose busulfan administration, Bone Marrow Transplant. 2002; 29: 963-965.
15. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 155-165.
16. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525-530.
17. Hassan M, Ljungman P, Bolme P, Ringde O, Syruckova Z, Beà ssy A et al. Busulfan bioavailability. Blood 1994; 84: 2144-2150.
18. Li X, Ruiz CH, Koenig M, Cameron MD. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism based inactivators and the proposed bio-activation pathways. Drug Metab Dispos 2009; 37: 1242-1250.
19. Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008; 14: 1936-1949.
20. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002; 8: 619-624.